

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-57. (CANCELED)

58. (NEW) A polynucleotide comprising:

a) a polynucleotide encoding a site III polypeptide sequence of a lyssavirus glycoprotein from a genotype GT1 strain, wherein the polynucleotide does not encode an entire lyssavirus glycoprotein;

b) a polynucleotide encoding a site II polypeptide sequence of a lyssavirus glycoprotein from genotype GT5;

c) a polynucleotide encoding a transmembrane domain of a transmembrane protein; and

d) a polynucleotide encoding a cytoplasmic domain of a transmembrane protein.

59. (NEW) The polynucleotide of claim 58, wherein said polynucleotide further comprises a heterologous polynucleotide encoding a peptide, polypeptide, or protein other than a lyssavirus glycoprotein or a peptide or polypeptide fragment of a lyssavirus glycoprotein.

60. (NEW) The polynucleotide of claim 59, wherein the heterologous polynucleotide encodes a B cell epitope, or a CD8 cell epitope or both.

61. (NEW) A polypeptide encoded by the polynucleotide of claim 59.

62. (NEW) An immunogenic composition comprising the polypeptide of claim 61.

63. (NEW) The immunogenic composition of claim 62, wherein said composition induces humoral and cellular immunity.

64. (NEW) The immunogenic composition of claim 62, wherein said immunogenic composition induces a protective immune response.